eldecalcitol
Small moleculeexperimental
Eldecalcitol is an analog of calcitriol, the active form of vitamin D. — Wikipedia
Clinical trial activity
10 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
4
Earliest trial started Sep 1, 2004 (NCT00144456)
Timeline
Indications
Approved for
Mechanism of action
- Vitamin D receptorAGONIST
VDR agonist
Chemistry & pharmacology
Loading structure…
SMILES
C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)[C@@H](OCCCO)[C@@H]1O- Mol. weight
- 490.73 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEldecalcitol ↗
- ChEMBLCHEMBL4297608 ↗
Also known as
- 1α,25-dihydroxy-2β-(3-hydroxypropoxy)cholecalciferol
- 1α,25-dihydroxy-2β-(3-hydroxypropoxy)cholecalciferol
- 20-epi-1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin d3
- 20-epi-ed-71
- 20-epi-eldecalcitol
- 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin d3
- 2-(3-hydroxypropoxy)calcitriol
- 9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol, 2-(3-hydroxypropoxy)-, (1alpha,2beta,3beta,5z,7e)-
- ed 71
- ed-71
- ed-71
- ed-71
- ed-71
- eldecalcitol
- eldecalcitol
- eldecalcitol
- eldecalcitol
- eldecalcitol
- eldecalcitol
- eldecalcitol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07063797 | N/A | Aug 1, 2025 | Chinese Academy of Medical Sciences |
| NCT06385093 | Phase 4 | Jun 30, 2024 | Chinese Academy of Medical Sciences, Chinese SLE Treatment And Research Group |
| NCT06537115 | Phase 4 | Jun 16, 2024 | Zhejiang University |
| NCT05884372 | Phase 4 | Aug 31, 2023 | Chugai, Jiao Tong University |
| NCT05902078 | Phase 4 | Jun 30, 2023 | Chugai, Jiao Tong University |
| NCT05406050 | Phase 1 | Oct 20, 2020 | Qingdao University, ShangHai HaiHe Pharmaceutical |
| NCT03755193 | Phase 2 | Nov 24, 2018 | Shinshu University |
| NCT02306187 | Phase 1 | Dec 1, 2014 | Shinshu University |
| NCT01974167 | N/A | Dec 1, 2013 | e-GLORIA trial Protocol Review Committee, University of Tokushima |
| NCT00144456 | Phase 3 | Sep 1, 2004 | Chugai, University of Tokushima |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chugai | For profit | 3 | 1 | 2 | 2004 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 1 | 2 | 2024 |
| Jiao Tong University | Academic/Hospital | 2 | 2 | 1 | 2023 |
| Shinshu University | Academic/Hospital | 2 | 2 | 2 | 2014 |
| University of Tokushima | Academic/Hospital | 2 | 0 | 2 | 2004 |
| Chinese SLE Treatment And Research Group | Academic/Hospital | 1 | 1 | 1 | 2024 |
| e-GLORIA trial Protocol Review Committee | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Qingdao University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| ShangHai HaiHe Pharmaceutical | For profit | 1 | 0 | 1 | 2020 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2024 |
10 organizations
Page 1 / 1